Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Short-Term Debt issuances (2016 - 2024)

Cumberland Pharmaceuticals' Short-Term Debt issuances history spans 12 years, with the latest figure at $5.5 million for Q4 2024.

  • For Q4 2024, Short-Term Debt issuances changed N/A year-over-year to $5.5 million; the TTM value through Sep 2025 reached $5.5 million, down 86.58%, while the annual FY2024 figure was $38.5 million, 22.28% up from the prior year.
  • Short-Term Debt issuances for Q4 2024 was $5.5 million at Cumberland Pharmaceuticals, down from $11.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $20.0 million in Q1 2022 and bottomed at $5.5 million in Q4 2024.
  • The 5-year median for Short-Term Debt issuances is $14.0 million (2021), against an average of $12.8 million.
  • The largest annual shift saw Short-Term Debt issuances surged 88.24% in 2021 before it crashed 60.0% in 2023.
  • A 5-year view of Short-Term Debt issuances shows it stood at $15.0 million in 2020, then decreased by 6.67% to $14.0 million in 2021, then crashed by 55.71% to $6.2 million in 2022, then increased by 29.03% to $8.0 million in 2023, then tumbled by 31.25% to $5.5 million in 2024.
  • Per Business Quant, the three most recent readings for CPIX's Short-Term Debt issuances are $5.5 million (Q4 2024), $11.0 million (Q3 2024), and $11.0 million (Q2 2024).